share_log

港股异动 | 山东新华制药涨近10%领涨抗疫概念股,首个国产抗新冠口服药每瓶定价不到300元

Changes in Hong Kong stocks | Shandong Xinhua Pharmaceutical rose nearly 10% to lead anti-epidemic stocks. The first domestic anti-COVID-19 oral drug is priced at less than 300 yuan per bottle.

Zhitong Finance ·  Aug 8, 2022 10:34

Anti-epidemic concept stocks rose collectively, as of press timeShandong Xinhua Pharmaceutical Co. (00719.HK) $Rose 9.89% to HK $5.11$Development Pharmaceutical Industry-B (09939.HK) $Rose 1.93% to HK $13.74$Tengshengbo Medicine-B (02137.HK) $Rose 2.96% to HK $8.7$Shanghai Fosun Pharmaceutical (02196.HK) $It rose 1.25% to HK $28.3.

On the news side, according to Henan True Biotechnology Co., Ltd., at present, the price of Azvudine tablets for the treatment of COVID-19 is initially set at less than 300 yuan per bottle, 35 tablets per bottle and 1mg per tablet. Prior to this, the State Drug Administration conducted emergency examination and approval in accordance with the relevant provisions of the Drug Administration Law and in accordance with the special drug examination and approval procedures, and conditionally approved the application for registration of COVID-19 indications for additional treatment of azifudine tablets in Henan Real Biotechnology Co., Ltd.

Edit / ruby

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment